{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"7.4","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Estimated using the Kaplan-Meier method.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Afatinib)"}],"paramType":"MEDIAN","populationDescription":"Analysis population includes those in the main Phase II study","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Median Overall Survival (OS) Time","type":"SECONDARY","unitOfMeasure":"months"}